Very long-chain fatty acids drive 1-deoxySphingolipid toxicity

A Adam Majcher G Gergely Karsai E Elkhan Yusifov M Martina Schaettin E Ermanno Malagola P Peter Horvath J Jinmei Li (NHC Key Laboratory of Biotechnology for Microbial Drugs, State Key Laboratory of Bioactive Substance & Function of Natural Medicines, Institute of Medicinal Biotechnology) S Sofía Rodriguez-Gallardo K Kuniyoshi Shimizu G Gai Zhibo R Raghvendra Dubey T Tim Peterson T Takeshi Harayama T Thorsten Hornemann

Abstract

Abstract 1-Deoxysphingolipids (1-deoxySLs) are atypical sphingolipids formed when serine palmitoyltransferase incorporates L-alanine instead of L-serine. Elevated 1-deoxySLs are associated with hereditary sensory neuropathy type 1 and diabetic neuropathy, but the molecular basis of their toxicity remains unclear. Here we show that toxicity is mediated by very long-chain (VLC) 1-deoxy-dihydroceramides (1-deoxyDHCer), particularly nervonyl-1-deoxyDHCer (m18:0/24:1) and lignoceryl-1-deoxyDHCer (m18:0/24:0). Using a CRISPR interference screen, we identify ELOVL1 and CERS2 as essential enzymes driving the formation of these toxic species. Genetic modulation or pharmacological inhibition of ELOVL1 prevents VLC 1-deoxyDHCer accumulation, rescuing the toxicity in cellular and neuronal models. Mechanistic studies reveal that m18:0/24:1 disrupts mitochondrial integrity and induces the mitochondrial permeability transition pore formation and BAX activation, leading to cell death. These findings establish a direct link between 1-deoxySL chemical structure and cytotoxicity and highlight ELOVL1 inhibition as a potential therapeutic strategy for 1-deoxySL-associated diseases.

Article Details

Volume / Issue Vol. 16, Issue 1
Published November 26, 2025
ISSN 2041-1723
Publisher Nature Portfolio

Journal Info

Nature Communications

Nature Portfolio

ISSN: 2041-1723 Open Access Life Sciences

Authors (14)

A

Adam Majcher

G

Gergely Karsai

E

Elkhan Yusifov

M

Martina Schaettin

E

Ermanno Malagola

P

Peter Horvath

J

Jinmei Li

NHC Key Laboratory of Biotechnology for Microbial Drugs, State Key Laboratory of Bioactive Substance & Function of Natural Medicines, Institute of Medicinal Biotechnology

S

Sofía Rodriguez-Gallardo

K

Kuniyoshi Shimizu

G

Gai Zhibo

R

Raghvendra Dubey

T

Tim Peterson

T

Takeshi Harayama

T

Thorsten Hornemann